View ValuationCuratis Holding 将来の成長Future 基準チェック /06現在、 Curatis Holdingの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Jun 14Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026Curatis Holding AG increased earnings guidance for the financial year 2026. for the year, the company is forecasting a revenue growth of approximately 40%, in contrast to the previous outlook of over 25%. Under the new guidance, Curatis projects revenuesof approximately CHF 15 million in 2026, up from CHF 10.8 million in 2025.すべての更新を表示Recent updatesお知らせ • Jun 14Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026Curatis Holding AG increased earnings guidance for the financial year 2026. for the year, the company is forecasting a revenue growth of approximately 40%, in contrast to the previous outlook of over 25%. Under the new guidance, Curatis projects revenuesof approximately CHF 15 million in 2026, up from CHF 10.8 million in 2025.お知らせ • Jun 12Curatis Holding AG to Report First Half, 2026 Results on Sep 21, 2026Curatis Holding AG announced that they will report first half, 2026 results on Sep 21, 2026Board Change • May 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Silvio Inderbitzin is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Curatis Holding は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:26U - アナリストの将来予測と過去の財務データ ( )CHF Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202511-1-3-1N/A9/30/202510-2-2-1N/A6/30/202510-2-1-1N/A3/31/20259-3-1-1N/A12/31/20247-4-1-1N/A9/30/20244-28-1-1N/A6/30/20242-51-1-1N/A3/31/20241-50-1-1N/Aアナリストによる今後の成長予測収入対貯蓄率: 26Uの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 26Uの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 26Uの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 26Uの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 26Uの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 26Uの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/30 06:23終値2026/06/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curatis Holding AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Bob PoolerValuationLAB AG
お知らせ • Jun 14Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026Curatis Holding AG increased earnings guidance for the financial year 2026. for the year, the company is forecasting a revenue growth of approximately 40%, in contrast to the previous outlook of over 25%. Under the new guidance, Curatis projects revenuesof approximately CHF 15 million in 2026, up from CHF 10.8 million in 2025.
お知らせ • Jun 14Curatis Holding AG Increases Earnings Guidance for the Financial Year 2026Curatis Holding AG increased earnings guidance for the financial year 2026. for the year, the company is forecasting a revenue growth of approximately 40%, in contrast to the previous outlook of over 25%. Under the new guidance, Curatis projects revenuesof approximately CHF 15 million in 2026, up from CHF 10.8 million in 2025.
お知らせ • Jun 12Curatis Holding AG to Report First Half, 2026 Results on Sep 21, 2026Curatis Holding AG announced that they will report first half, 2026 results on Sep 21, 2026
Board Change • May 20No independent directorsThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Non-Executive Director Silvio Inderbitzin is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Sep 18Curatis Holding AG Announces FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 - Corticorelin on Track for Phase 3Curatis Holding AG received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary to solid tumor brain metastases. The Phase 3 will utilize an adaptive trial design consisting of a dose optimization lead-in and confirmatory segment. PTBE occurs in association with many primary and metastatic (secondary) brain tumors, often in connection with metastases caused by lung cancer, breast cancer, melanoma and colorectal cancer. PTBE results in impairment of brain function due to the accumulation of extracellular fluid around the tumor and can cause symptoms such as headaches, vomiting and neurological dysfunction such as paralysis, speech disorders, visual problems and altered mental status. Standard of care treatment for PTBE is the use of corticosteroids which frequently have serious side effects such as severe myopathy, impared glucose metabolism, muscle wasting, abnormal weight gain, oeoporosis, gastritis, gastrointestinal bleeding, hypertension and personality changes. Additionally, corticosteroids can also counteract certain cancer therapies such as chemotherapy or emerging immunotherapies. In the US alone, more than 150,000 patients suffer from PTBE.
お知らせ • May 23Curatis Holding AG Announces Executive ChangesCuratis Holding AG announced strengthening the team with Kirsty Crame, MD, as Chief Medical Officer and Timm Trenktrog, PhD, as Head of Chemistry, Manufacturing and Controls (CMC). Kirsty Crame, MD, was educated at the University of Amsterdam as a Doctor of Medicine. She has more than 12 years of experience in clinical development, of which more than 10 years have been in the field of immuno-oncology in a variety of indications for rare and non-rare diseases. Kirsty was previously a member of the Executive Committee and Vice President of Clinical Strategy and Development at Medigene, a German biotech company specializing in the development of highly innovative, T-cell receptor-directed cancer therapies. Prior to that, she was Director of Clinical Development at Gadeta, a Dutch company specializing in the development of novel immunotherapies. Kirsty will support Curatis in the preparation and conduct of the pivotal Phase 3 study with C-PTBE-01 and also brings extensive experience in regulatory affairs. Timm Trenktrog, PhD, worked for Actelion Pharmaceuticals Ltd. in Switzerland for more than 19 years, most recently as Vice President and Head of Technical Operations on the Executive Board. As a leading pharmaceutical expert, he lectured for over 10 years at the ETH Zurich on quality, production and technical development. Timm will support Curatis in the area of technical development and manufacturing (CMC) for C-PTBE-01 to ensure smooth production and the highest quality of the active ingredient, dosage form and final product.